ClinicalTrials.gg
TerminatedNCT05834543Updated Jul 16, 2025

Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

A Phase 1/2 interventional study of TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin and Penpulimab injection, Paclitaxel, Cisplatin in Advanced Esophageal Squamous Cell Carcinoma, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Terminated at 10 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 401 studies in Esophageal Squamous Cell Carcinoma with a site in China — 174 open to participants now, 213 under way, 32 of them phase 3. Esophageal Squamous Cell Carcinoma · China.

Enrollment
284th of 351
34 · median 70
Started
2023
with 38 others
Phase 1/2
17 of 401
9 open now
Registered
223rd of 401
by date

Among the 401 studies in Esophageal Squamous Cell Carcinoma with a site in China, this one is the 284th largest by enrollment of the 351 interventional ones that give a count, is one of 39 that started in 2023, is one of 17 in phase 1/2, and was the 223rd registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

174 of the 401 studies in Esophageal Squamous Cell Carcinoma with a site in China are open now. Recruiting first, the newest first:

169 more — sign in →

All 174 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 401 studies in Esophageal Squamous Cell Carcinoma with a site in China, or all of them as a file.
02

Study summary

To investigate the efficacy and safety of TQB2618 injection combined Penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic esophageal squamous cell carcinoma compared with Penpulimab combined chemotherapy.

The primary efficacy outcomes are progression free survival (PFS) and objective response rate (ORR).

03

Conditions studied

  • Advanced Esophageal Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Nonresectable locally advanced, recurrent or esophageal squamous cell carcinoma (excluding mixed adenosquamous cell carcinoma) confirmed by histopathology or cytology;
  • For Cohort 1: Those who have not received systematic treatment, or have relapse at least 6 months after the (new) treatment/radical radiotherapy and chemotherapy; For Cohort 2: received platinum-based chemotherapy and immuno (PD-1/PD-L1, etc.) treatment and failed, the best effect of front-line immunotherapy CR, PR, or SD lasted ≥ 24 weeks, and there was evidence of imaging progression;
  • Age: 18-75 years old (calculated based on the date of signing the ); (ECOG) score: 0-1; The expected survival period is more than 3 months;
  • At least one was confirmed according to 1.1 standard; Measurable lesions should not have received local treatment such as radiotherapy (lesions located in the area of previous radiotherapy treated can also be selected as target lesions if progression is confirmed);
  • The main organs function well and meet the following standards:

    1. The blood routine examination should meet the following requirements: (no blood transfusion, no use of hematopoietic stimulator drugs for correction within 14 days before the examination)

      1. content (HB) ≥ 90g/L;
      2. (ANC) ≥ 1.5 ×10\^9/L;
      3. count (PLT) ≥ 100 × 10\^9/L.
    2. Biochemical examination shall meet the following standards:

      1. Total serum (TBIL) ≤ 1.5 times of the value (ULN);
      2. (ALT) and aspartate aminotransferase (AST) ≤ 2.5ULN; In case of liver metastasis, ALT and AST ≤ 5ULN;
      3. Serum creatinine (Cr) ≤ 1.5ULN or rate (CCr) ≥ 60ml/min; (Cockcroft-Default formula);
    3. Coagulation function is sufficient, defined as (INR) or prothrombin time (PT) ≤ 1.5 times ULN;
    4. Thyroid function examination shall meet the following standards: thyroid stimulating hormone (TSH) ≤ ULN; If abnormal, exam the level of T3 and T4, patients with abnormal T3 and T4 can be enrolled.
    5. Cardiac color doppler evaluation: (LVEF) ≥ 50%.
    6. Female subjects of childbearing age should agree to use (such as intrauterine devices, contraceptives or condoms) during the study period and within 6 months after the end of the study; The serum pregnancy test was negative within 7 days before enrollment and must be a non-lactating subject; Male subjects should agree to use contraception during the study period and within 6 months after the end of the study.
    7. Subjects volunteered to join the study and signed the informed consent form, with good compliance;

Exclusion criteria

Exclusion Criteria:

  • Known esophageal squamous cell carcinoma which tended to complete obstruction under endoscope and needed interventional treatment to relieve obstruction;
  • Increased risk of bleeding or fistula caused by tumor significantly invading adjacent organs (aorta or trachea);
  • After esophageal or tracheal stent implantation;
  • For Cohort 1: Patients who have used paclitaxel in chemotherapy and have relapse or within one year (note: those who have relapse or metastasis for more than one year can be included in the study); Patients who received cisplatin dose ≥ 300mg/m2 in the year before;
  • The load of liver metastases accounts for more than 50% of the whole liver volume;
  • For Cohort 1: Those who have received or anti-PD-L1/PD-L2, TIM-3, CTLA-4 drugs or other therapies that act on T-cell co-stimulation targets or checkpoints in the past; For Cohort 2: Patients who have previously received BET inhibitor treatment.
  • Patients with any serious and/or uncontrollable diseases, including:

    1. Have any clinical cardiovascular symptoms or diseases with poor control, including but not limited to: patients with poor blood pressure control using antihypertensive drugs (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg); (NYHA) grade II or above heart failure; Unstable angina pectoris; Myocardial infarction occurred in the past one year; Patients with arrhythmia ( ≥ 450ms (male), QTc ≥ 470ms (female)), or patients with (LVEF)\<50% according to cardiac color Doppler examination;
    2. Active or uncontrolled serious infection (≥ NCI CTC AE level 2 infection);
    3. Liver diseases such as cirrhosis, decompensated liver disease, chronic active hepatitis ( virus (HBV) reference: HBsAg positive, and HBV DNA detected value exceeds the value; virus (HCV) reference: HCV antibody positive, and HCV virus titer detected value exceeds the upper limit of normal value); Note: Subjects with positive hepatitis B surface antigen or core antibody and hepatitis C patients who meet the inclusion conditions need to receive continuous antiviral treatment to prevent virus activation.
    4. Poor control of diabetes (Fasting Blood Glucose (FBG)>10mmol/L);
    5. Urine routine test showed that urine protein ≥++, and confirmed that the 24-hour urine protein content was more than 1.0 g;
    6. Renal failure requiring hemodialysis or peritoneal dialysis;
    7. Those who have epilepsy and need treatment;
  • Major surgery (craniotomy, thoracotomy or laparotomy) has been performed within 4 weeks before the first dose of the study or is expected to require major surgery during the study treatment.
  • A history of gastrointestinal perforation and/or fistula within 6 months before treatment; Or have experienced arterial/venous thrombosis events, such as cerebrovascular accident (including ), deep venous thrombosis and pulmonary embolism;
  • Known central nervous system metastasis and/or cancerous meningitis;
  • Ascites with clinical significance, including any ascites that can be found in physical examination. For ascites that have been treated in the past or still need to be treated at present, subjected can be included if only a small amount of ascites is shown by imaging and without symptoms;
  • Patients with equal amount of effusion in both sides of the chest, or a large amount of effusion in one side of the chest, or who have caused respiratory dysfunction and need drainage;
  • Wounds or fractures that have not been cured for a long time;
  • Esophageal squamous cell carcinoma patients with active bleeding of the primary lesion within 2 months; Pulmonary hemorrhage with NCI CTC AE grade>1 occurred within 4 weeks before enrollment; Bleeding at other sites with NCI CTC AE grade>2 occurred within 4 weeks before enrollment; Patients with bleeding tendency (such as active gastrointestinal ulcer) or undergoing thrombolytic or anticoagulant therapy such as warfarin, heparin or its analogues;
  • There is active pulmonary tuberculosis, or there is a history of active tuberculosis infection within one year before enrollment, or there is a history of active tuberculosis infection more than one year before enrollment, but they have not received treatment;
  • Interstitial lung disease requiring hormone treatment;
  • Uncontrolled metabolic disorder or other non-malignant tumor organ or systemic disease or cancer secondary reaction, which may lead to higher medical risk and/or uncertainty of survival evaluation;
  • Patients with significant malnutrition (such as the need for continuous parenteral nutrition ≥ 7 days), patients with (BMI)\<18.5kg/m2 or weight loss ≥ 10% in the two months before screening.
  • Those who have a history of abuse of psychotropic substances and are unable to quit or have mental disorders;
  • Have a history of immunodeficiency, including positive or other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation and hematopoietic stem cell transplantation;
  • History of other primary malignant tumors, except for the following: 1) Malignant tumors completely relieved for at least 2 years before enrollment and no other treatment is required during the study period; 2) Nonmelanoma skin cancer or malignant freckle-like nevus with sufficient treatment and no evidence of disease recurrence; 3) Carcinoma in situ with sufficient treatment and no evidence of disease recurrence;
  • Those who are allergic to the study drug or its , or to similar drugs;
  • Pregnant or lactating female patients;
  • There is an unrelieved toxic reaction higher than NCI CTC AE level 1 caused by any previous treatment before the first medication, excluding hair loss;
  • Active diseases requiring systemic treatment (such as the use of disease relief drugs, corticosteroids or ) have occurred within 2 years before the first medication. Replacement therapy (such as thyroxine, insulin or physiological corticosteroids for adrenal or pituitary insufficiency) is not considered as systemic treatment;
  • Have received systemic glucocorticoid therapy (dose>10mg/day prednisone or other effective hormones) or any other form of immunosuppressive therapy within 2 weeks before the start of the study;
  • The history of inoculation within 28 days before the first administration or the planned live attenuated vaccine inoculation during the study period;
  • Have received chemotherapy, radiotherapy or other anti-tumor treatment within 4 weeks before the first medication ( is calculated from the end of the last treatment); Note: Those who have received local radiotherapy in the past can be enrolled if the following conditions are met: the end of radiotherapy is more than 3 weeks from the beginning of study treatment (brain radiotherapy is more than 2 weeks); And the target focus selected in this study is not in the radiotherapy area; Or the target lesion is located in the radiotherapy area, but progress has been confirmed.
  • Participated in clinical trials of other anti-tumor drugs within 4 weeks before the first medication (the washout period is calculated from the end of the last treatment);
  • Within 2 weeks before the first use of drug, the subjects have received the treatment of traditional Chinese medicines (including compound cantharides capsule, Kangai injection, Kanglaite capsule/injection, Aidi injection, Brucea javanica oil injection/capsule, Xiaoaiping tablet/injection, cinobufagin capsule, etc.) with anti-tumor indications specified in the drug labelling approved by National Medical Products Administration (NMPA).
  • Subjects who, according to the judgment of the investigator, have serious concomitant diseases that endanger the safety of the patient or affect the completion of the study, or who are considered that are not suitable for enrollment due to other reasons .
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    TQB2618 injection +Penpulimab injection+Chemotherapy

    Experimental group in Cohort 1. TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin, 21 days as a treatment cycle. After 4\~6 cycles, TQB2618 injection combined Penpulimab injection, 21 days as a treatment cycle.

    Drug: TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin

  • Active comparator
    Penpulimab injection+Chemotherapy

    Active comparator group in Cohort 1. Penpulimab injection, Paclitaxel, Cisplatin, 21 days as a treatment cycle. After 4\~6 cycles, Penpulimab injection 21 days as a treatment cycle.

    Drug: Penpulimab injection, Paclitaxel, Cisplatin

  • Experimental
    TQB2618 injection +Penpulimab +TQB3617capsules

    Cohort 2. TQB2618 injection, Penpulimab injection, 21 days as a treatment cycle. TQB3617 capsules are administered on Day 1 and Day 14, 21 days as a treatment cycle.

    Drug: TQB2618 injection, Penpulimab injection, TQB3617capsules

Interventions

  • DrugTQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin

    Drug pages: Anti-TIM-3 Monoclonal Antibody TQB2618 · Penpulimab · Paclitaxel · Cisplatin

    TQB2618 injection:Anti-TIM-3 monoclonal antibody. Penpulimab injection:Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1). Paclitaxel and Cisplatin are chemotherapy.

  • DrugPenpulimab injection, Paclitaxel, Cisplatin

    Drug pages: Penpulimab · Paclitaxel · Cisplatin

    Penpulimab injection:Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1). Paclitaxel and Cisplatin are chemotherapy.

  • TQB2618 injection:Anti-TIM-3 monoclonal antibody. Penpulimab injection:Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).

06

What researchers measure

Primary outcomes

  1. PFS

    The time from the first administration of the drug to disease progression or death (whichever occurs first).

    Time frame: Baseline up to two years.

  2. ORR

    According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and iRECIST, the proportion of subjects whose tumors are evaluated as complete response(CR) and partial response(PR) by subcenter imaging evaluation. It is recorded from the first use of the drug to disease progression or initiation of a new anticancer treatment.

    Time frame: Baseline up to two years.

Secondary outcomes

  1. Overall survival (OS)

    From randomization to the time of death from any cause.

    Time frame: Baseline up to death event, assessed up to 2 years.

  2. Disease Control Rate (DCR)

    The percentage of participants with complete response (CR), partial response (PR), or stable disease (SD) at 6 weeks or greater than or equal to as determined by investigators according to Response evaluation criteria in solid tumors (RECIST) 1.1.

    Time frame: Baseline to up to two years.

  3. Duration of Remission (DOR)

    The period from firstly-recorded objective tumor response (CR or PR) to firstly-recorded objective tumor progression or death due to any cause (whichever occurs first).

    Time frame: Baseline to up to two years.

  4. Incidence of adverse events (AEs)

    All adverse medical events that occur after the subject receives the investigational drug may be manifested as symptoms, signs, disease, or laboratory abnormalities, but are not necessarily causally related to the investigational drug. The adverse events were evaluated according to the National Cancer Institute standard for common toxic reactions (NCI-CTC v5.0).

    Time frame: Baseline to up to two years.

  5. Severity of adverse events (AEs)

    All adverse medical events that occur after the subject receives the investigational drug may be manifested as symptoms, signs, disease, or laboratory abnormalities, but are not necessarily causally related to the investigational drug. The severity of adverse events were evaluated according to the National Cancer Institute standard for common toxic reactions (NCI CTC) V5.0.

    Time frame: Baseline to up to two years.

  6. Incidence of serious adverse events (SAEs)

    It refers to adverse medical events such as death, life-threatening, permanent or serious disability or loss of function, hospitalization or prolonged hospitalization, and congenital abnormalities or birth defects after the subject receives the experimental drug.

    Time frame: Baseline to up to two years.

07

Study locations

10 sites
  • Tongling People's Hospital
    Tongling, Anhui 244099, China
  • The First Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui 241000, China
  • AnYang Tumor Hospital
    Anyang, Henan 455000, China
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan 471003, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450000, China
  • Zhumadian Central Hospital
    Zhumadian, Henan 463003, China
  • Affiliated Hospital of Jining Medical College
    Jining, Shandong 272007, China
  • Changzhi People's Hospital
    Changzhi, Shanxi 046000, China
  • Heping Hospital Affiliated to Changzhi Medical College
    Changzhi, Shanxi 046000, China
  • Jincheng General Hospital
    Jincheng, Shanxi 048000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Oct 2024, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2023
First posted
Apr 28, 2023
StartActual
May 26, 2023
Primary completionActual
Oct 23, 2024
CompletionActual
Mar 3, 2025
Last update
Jul 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05834543
Responsible party
Sponsor
First posted
Apr 28, 2023
Start date
May 26, 2023
Primary completion
Oct 23, 2024
Completion
Mar 3, 2025
Last update
Jul 16, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-TIM-3 Monoclonal Antibody TQB2618 · Penpulimab · Paclitaxel · Cisplatin

Start the discussion